🧬 5 years of KEYNOTE-426: proof of lasting benefit + biomarker clues 📊 Pembrolizumab + Axitinib vs Sunitinib in advanced RCC ✅ OS: 47.2 vs 40.8 mo (HR 0.84) ⏳ PFS: 15.7 vs 11.1 mo (HR 0.69) 🎯 ORR: 60.6% vs 39.6% (CR 11.6% vs 4%) 🔒 26% of responders on combo still in

Wild Landscape Ongoing or completed phase II/III trials in intermediate- and high-risk NMIBC -- Badrinath Konety, MD, MBA UroToday.com #SCSAUA25 South Central Section of the AUA

📄International Journal of Surgery Protocols “Research protocol for the evaluation of TriNetra™ Prostate: a circulating tumor cell-based diagnostic tool for prostate cancer” 🔬 This multicenter prospective study will evaluate a novel blood-based liquid biopsy that detects

🚨 New data in advanced penile cancer: The HERCULES trial (LACOG 0218) shows Pembrolizumab + platinum chemo achieved ~40% ORR, median PFS 5.4 mo & OS 9.6 mo with manageable toxicity. Biomarkers (HPV-16, TMB) may guide benefit. Read 👉 JAMA Oncology

🆕 Editorial in European Urology by Sigrid Carlsson: MRI can reshape prostate cancer screening. 🔹 First-line MRI: ↑ detection, ↑ resource use 🔹 2nd-stage MRI after PSA: ↓ unnecessary biopsies, ↑ csPCa yield 🔹 Quality & risk-adapted pathways are key Read 👉

🚫 In >2400 men with unfavourable risk #ProstateCancer, whole-pelvic RT (WPRT) ❌ did not improve 10-yr OS or DFS vs prostate-only RT (68% both arms). 🔹 PC-specific survival 98% 🔹 Slight ↓ in biochemical failure with WPRT 🔹 More grade 2 GI adverse events ⁉️how to reconcile

Bladder only vs. whole pelvis radiotherapy in trimodality treatment for lymph node negative urothelial muscle-invasive #BladderCancer: a systematic review and meta-analysis. Presented by Alyssa Anne Granda, MD Jose R. Reyes Memorial Medical Center. #ASTRO25 written coverage by Rashid K. Sayyid UA Urology >

El día de ayer finalizamos el IV Curso de Urología Oncológica, desde la Sección de Docencia y toda la Junta Directiva de la Sociedad Colombiana de Urología estamos muy agradecidos y motivados para continuar creciendo por el mejoramiento de la patología urológica.

Neeraj Agarwal, MD, FASCO The Lancet Oncology UroToday.com OncoAlert Prostate Cancer Foundation Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Arun Azad Vivek Subbiah, MD Shilpa Gupta Petros Grivas Andrea Apolo, M.D. Umang Swami, MD, MSCI, FASCO Axel S. Merseburger Yüksel Ürün Nice study, but surprised by the conclusion that “combining niraparib with AAP significantly improved rPFS in patients with mCSPC harbouring BRCA1/BRCA2 or other HRR gene alterations”, when HR for patients without BRCA1/2 alterations is 0.81 (95% confidence interval:

🚀 New in European Urology – Surgery in Motion Single-port Antegrade Robotic Lymphadenectomy (SPARL): a new frontier for minimally invasive management of lymph nodes in penile cancer. Through a single infraumbilical incision, SPARL allows bilateral inguinal ± pelvic

#RenalCancer #Epidemiology Update: #Incidence, #Mortality, #Survival, #GeneticPredisposition, and #RiskFactors • 🌍 434,840 cases and 11,953 deaths in 2022 • 📈 Incidence projected to increase by +72% by 2050 • 📈 Mortality projected to increase by +96% by 2050 • 📊

The AlphaBet trial Peter Mac Cancer Centre The Lancet Oncology release today ESMO - Eur. Oncology #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active. ✅ No dose-limiting toxicities 💪 PSA-50% decline in 55% 🧬 Supports future

Optimised use of radioligand therapy in mCRPC #ESMO25

🚨First ctDNA- guided adjuvant IO trial positive for OS in MIBC Incredible data!

On-treatment serum prostate specific antigen and metastatic burden at treatment start: landmark analysis of 7129 patients starting long-term androgen deprivation and randomised in the STAMPEDE platform protocol. Presentation by Mahaz Kayani MRC Clinical Trials Unit at UCL. #ESMO25 written coverage by

Aggressive variant #ProstateCancers. Presentation by Ana Aparicio MD Anderson Cancer Center. #ESMO25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3J63j8z ESMO - Eur. Oncology

Yüksel Ürün National Cancer Institute Michael Hofman Arun Azad silke gillessen Neeraj Agarwal, MD, FASCO Thomas Zilli Piet Ost Emre Yekedüz Declan Murphy Deborah Mukherji Gianluca Giannarini Thanks 🎈Excellent members on the working group who understand nuances of BCR 🎈Pragmatic recommendations in the context of existing data David Einstein #BCR #ProstateCancer #PSMA+BCR 🔗Link to 📖 article Journal of Clinical Oncology ASCO ascopubs.org/doi/10.1200/JC…

Ultra-low PSA response (in #ARANOTE correlates with greatly improved clinical outcome. Presentation by Jack Andrews Mayo Clinic. #WSAUA25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4hEUNKg Western Section AUA

New State-of-the-Art Review: “The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies” - just published in the November issue of European Urology European Urology by Dr. Benjamin Maughan and colleagues. It’s a great honor to be part of this amazing

Clinical and #Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive #ProstateCancer European Urology #PSMA sciencedirect.com/science/articl…